Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

This is an open label, non-randomized, single cohort, phase II trial of Belzutifan for participants with recurrent or persistent clear cell ovarian carcinoma (CCOC) and clear cell carcinoma of other gynecologic malignancies. Belzutifan is a targeted drug therapy, which is a type of cancer treatment that targets specific molecules that cancer cells need to grow and spread. The U.S. Food and Drug Administration (FDA) has not approved Belzutifan for ovarian cancer, or other gynecologic cancers, but it has been approved for other uses. The study procedures include screening for eligibility, in-clinic visits, electrocardiograms (ECGs), Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, and blood and urine tests. It is expected up to 32 participants will take part in this research study. Merck \& Company is supporting this research study by providing funding and the study drug, Belzutifan.